Visterra Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
150
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$629K
- Investors
-
1
Visterra General Information
Description
Operator of a clinical-stage biopharmaceutical company designed to treat infectious diseases caused by organisms. The company designs and engineers antibody-based biological products for the treatment of non-infectious diseases that are not being adequately addressed, enabling healthcare providers and researchers to seek the significant unmet need for effective therapies.
Contact Information
Website
www.visterrainc.com(Operating Subsidiary)
Corporate Office
- 275 Second Avenue
- 4th Floor
- Waltham, MA 02451
- United States
Corporate Office
- 275 Second Avenue
- 4th Floor
- Waltham, MA 02451
- United States
Visterra Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 31-Mar-2025 | $629K | Completed | Generating Revenue | ||
| 9. Merger/Acquisition | 31-Aug-2018 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series C) | 05-Oct-2017 | Completed | Generating Revenue | |||
| 7. IPO | 10-Feb-2017 | Cancelled | Generating Revenue | |||
| 6. Grant | 29-Sep-2015 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series B) | 15-May-2014 | Completed | Pre-Clinical Trials | |||
| 4. Later Stage VC (Series A) | 02-Dec-2013 | Completed | Startup | |||
| 3. Debt - General | 17-Sep-2010 | Completed | Startup | |||
| 2. Seed Round | 07-Dec-2009 | $3.2M | $5.2M | Completed | Startup | |
| 1. Seed Round | 28-Jan-2008 | $2M | $2M | Completed | Startup |
Visterra Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A | 32,447,072 | $0.000100 | $1 | $1 | 1x | $1 | 28.22% | |
| Seed | 6,178,926 | $0.000100 | $1 | $1 | 1x | $1 | 5.37% |
Visterra Comparisons
Industry
Financing
Details
Visterra Competitors (74)
One of Visterra’s 74 competitors is NGM Biopharmaceuticals, a Private Equity-Backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NGM Biopharmaceuticals | Private Equity-Backed | South San Francisco, CA | ||||
| CV6 Therapeutics | Venture Capital-Backed | Belfast, United Kingdom | ||||
| Cellestia | Venture Capital-Backed | Basel, Switzerland | ||||
| Oxford Biotherapeutics | Private Equity-Backed | Oxford, United Kingdom | ||||
| Adrenomed | Venture Capital-Backed | Hennigsdorf, Germany |
Visterra Patents
Visterra Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20260337287-A1 | Methods of using antibodies to a proliferation-inducing ligand (april) | Pending | 28-Mar-2025 | ||
| WO-2026207341-A2 | Methods of using antibodies to a proliferation-inducing ligand (april) | Pending | 28-Mar-2025 | ||
| WO-2026207341-A3 | Methods of using antibodies to a proliferation-inducing ligand (april) | Pending | 28-Mar-2025 | ||
| US-20260028384-A1 | Use of il-2 variant for treating kidney transplant rejection | Pending | 17-Apr-2024 | ||
| WO-2025221954-A1 | Use of il-2 variant for treating kidney transplant rejection | Pending | 17-Apr-2024 | A61P37/06 |
Visterra Signals
Visterra Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Allegheny Financial Group | Asset Manager | Minority | ||
| CTI Life Sciences Fund | Venture Capital | Minority | ||
| Cycad Group | Venture Capital | Minority | ||
| Flagship Pioneering | Venture Capital | Minority |
Visterra FAQs
-
When was Visterra founded?
Visterra was founded in 2008.
-
Where is Visterra headquartered?
Visterra is headquartered in Waltham, MA.
-
What is the size of Visterra?
Visterra has 150 total employees.
-
What industry is Visterra in?
Visterra’s primary industry is Drug Discovery.
-
Is Visterra a private or public company?
Visterra is a Private company.
-
What is Visterra’s current revenue?
The current revenue for Visterra is .
-
How much funding has Visterra raised over time?
Visterra has raised $629K.
-
Who are Visterra’s investors?
Alexandria Venture Investments, Allegheny Financial Group, CTI Life Sciences Fund, Cycad Group, and Flagship Pioneering are 5 of 16 investors who have invested in Visterra.
-
Who are Visterra’s competitors?
NGM Biopharmaceuticals, CV6 Therapeutics, Cellestia, Oxford Biotherapeutics, and Adrenomed are some of the 74 competitors of Visterra.
-
When was Visterra acquired?
Visterra was acquired on 31-Mar-2025.
-
Who acquired Visterra?
Visterra was acquired by Otsuka Pharmaceutical.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process